Literature DB >> 30498724

"A rose by any other name": does defining extreme phenotypes add to the management of multiple sclerosis?

Evan A Jolliffe1, Brian G Weinshenker1.   

Abstract

Entities:  

Year:  2018        PMID: 30498724      PMCID: PMC6230867          DOI: 10.21037/atm.2018.08.15

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


× No keyword cloud information.
  13 in total

1.  Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder.

Authors:  Ju-Hong Min; Byoung Joon Kim; Kwang Ho Lee
Journal:  Mult Scler       Date:  2011-12-06       Impact factor: 6.312

2.  Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome.

Authors:  D T Okuda; E M Mowry; A Beheshtian; E Waubant; S E Baranzini; D S Goodin; S L Hauser; D Pelletier
Journal:  Neurology       Date:  2008-12-10       Impact factor: 9.910

3.  Progressive solitary sclerosis: Gradual motor impairment from a single CNS demyelinating lesion.

Authors:  B Mark Keegan; Timothy J Kaufmann; Brian G Weinshenker; Orhun H Kantarci; William F Schmalstieg; M Mateo Paz Soldan; Eoin P Flanagan
Journal:  Neurology       Date:  2016-09-16       Impact factor: 9.910

4.  Treatment of Neuromyelitis Optica: Review and Recommendations.

Authors:  Dorlan J Kimbrough; Kazuo Fujihara; Anu Jacob; Marco A Lana-Peixoto; Maria Isabel Leite; Michael Levy; Romain Marignier; Ichiro Nakashima; Jacqueline Palace; Jérôme de Seze; Olaf Stuve; Silvia N Tenembaum; Anthony Traboulsee; Emmanuelle Waubant; Brian G Weinshenker; Dean M Wingerchuk
Journal:  Mult Scler Relat Disord       Date:  2012-10       Impact factor: 4.339

Review 5.  Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.

Authors:  Alan J Thompson; Brenda L Banwell; Frederik Barkhof; William M Carroll; Timothy Coetzee; Giancarlo Comi; Jorge Correale; Franz Fazekas; Massimo Filippi; Mark S Freedman; Kazuo Fujihara; Steven L Galetta; Hans Peter Hartung; Ludwig Kappos; Fred D Lublin; Ruth Ann Marrie; Aaron E Miller; David H Miller; Xavier Montalban; Ellen M Mowry; Per Soelberg Sorensen; Mar Tintoré; Anthony L Traboulsee; Maria Trojano; Bernard M J Uitdehaag; Sandra Vukusic; Emmanuelle Waubant; Brian G Weinshenker; Stephen C Reingold; Jeffrey A Cohen
Journal:  Lancet Neurol       Date:  2017-12-21       Impact factor: 44.182

6.  Immunosuppressive therapy is more effective than interferon in neuromyelitis optica.

Authors:  C Papeix; J-S Vidal; J de Seze; C Pierrot-Deseilligny; A Tourbah; B Stankoff; C Lebrun; T Moreau; P Vermersch; B Fontaine; O Lyon-Caen; O Gout
Journal:  Mult Scler       Date:  2007-01-29       Impact factor: 6.312

7.  Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis.

Authors:  Shanu F Roemer; Joseph E Parisi; Vanda A Lennon; Eduardo E Benarroch; Hans Lassmann; Wolfgang Bruck; Raul N Mandler; Brian G Weinshenker; Sean J Pittock; Dean M Wingerchuk; Claudia F Lucchinetti
Journal:  Brain       Date:  2007-02-04       Impact factor: 13.501

8.  Pure spinal multiple sclerosis: A possible novel entity within the multiple sclerosis disease spectrum.

Authors:  Jie Ping Schee; Shanthi Viswanathan
Journal:  Mult Scler       Date:  2018-05-17       Impact factor: 6.312

9.  Establishing long-term efficacy in chronic disease: use of recursive partitioning and propensity score adjustment to estimate outcome in MS.

Authors:  Douglas S Goodin; Jason Jones; David Li; Anthony Traboulsee; Anthony T Reder; Karola Beckmann; Andreas Konieczny; Volker Knappertz
Journal:  PLoS One       Date:  2011-11-30       Impact factor: 3.240

10.  International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.

Authors:  Dean M Wingerchuk; Brenda Banwell; Jeffrey L Bennett; Philippe Cabre; William Carroll; Tanuja Chitnis; Jérôme de Seze; Kazuo Fujihara; Benjamin Greenberg; Anu Jacob; Sven Jarius; Marco Lana-Peixoto; Michael Levy; Jack H Simon; Silvia Tenembaum; Anthony L Traboulsee; Patrick Waters; Kay E Wellik; Brian G Weinshenker
Journal:  Neurology       Date:  2015-06-19       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.